Video

Focusing on Improving Depression in HNC Survivors

Author(s):

Nosayaba Osazuwa-Peters, BDS, MPH, CHES

As cancer survivors are living longer thanks to new treatments, it is essential that health care providers and researchers put more focus on depression.

Now that patients with head and neck cancer (HNC) — as well as many other cancer types – are living much longer, it is essential that researchers and health care professionals recognize the importance of depression and quality-of-life issues, according to Nosayaba Osazuwa-Peters, BDS, MPH, CHES, Instructor, Department of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine.

Osazuwa-Peters’ recent research shed light on suicide rates in HNC survivors, which he noted were on the rise for all cancer types. Many suicide risk factors, such as depression and pain, are common in survivors, so it is imperative that signs of suicide are recognized in this population so individuals can get the help that they may need.

Related Videos
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Image of woman with black hair.
Image of man with black hair.
Image of woman with black hair.
Related Content
Image of Dr. Fakih.
February 27th 2025

ctDNA Alone ‘Not Sufficient’ When Monitoring Patients With Colorectal Cancer

Dr. Marwan Fakih
The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
Image of doctor with brown hair.
February 25th 2025

Some KRAS Mutations Associated With Worse Outcomes in Pancreatic Cancer

Dr. Vaia Florou
In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, researchers have found.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Illustration of neck.
February 20th 2025

Ficerafusp Alfa Trial Begins for Recurrent/Metastatic Head and Neck Cancer

Spencer Feldman
Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.
Dr. Robert Jones is a professor of Clinical Cancer Research at The University of Glasgow School of Cancer Sciences, in Scotland.
February 15th 2025

Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer

Dr. Robert Jones
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.